Drug Profile
rHIgM22
Alternative Names: M22; Remyelinating-monoclonal-antibody-Acorda-Therapeutics; sHIgM22Latest Information Update: 09 Apr 2024
Price :
$50
*
At a glance
- Originator Mayo Clinic
- Developer Acorda Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Myelin protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 09 Apr 2024 Discontinued - Phase-I for Multiple sclerosis in USA (IV) as no recent reports of development reported
- 29 Dec 2022 Suspended - Phase-I for Multiple sclerosis in USA (IV)
- 28 Mar 2021 No recent reports of development identified for phase-I development in Multiple-sclerosis in USA (IV, Infusion)